Document is current
Any future updates will be listed below
-
Authors
Wray, Rebecca https://orcid.org/0009-0003-5595-5170
Paverd, Hania https://orcid.org/0009-0004-5317-9080
Machado, Ines https://orcid.org/0000-0003-4160-9624
Barbieri, Johanna
Easita, Farhana
Edwards, Abigail R. https://orcid.org/0000-0003-0273-9549
Gallagher, Ferdia A.
Mendichovszky, Iosif A.
Mitchell, Thomas J. https://orcid.org/0000-0003-0761-9503
de la Roche, Maike https://orcid.org/0000-0002-0558-4119
Shields, Jacqueline D. https://orcid.org/0000-0003-2153-9710
Ursprung, Stephan
Wallis, Lauren
Warren, Anne Y. https://orcid.org/0000-0002-1170-7867
Welsh, Sarah J.
Crispin-Ortuzar, Mireia https://orcid.org/0000-0002-4351-3709
Stewart, Grant D. https://orcid.org/0000-0003-3188-9140
Jones, James O.
,
Couper, Niki
Hopcroft, Lisa E. M.
Hill, Robert
Matakidou, Athena
Caasi, Cara
Watson, James
Cross, Ruby
Burge, Sarah W.
George, Anne
Klatte, Tobias
Aho, Tevita F.
Armitage, James N.
Rossi, Sabrina Helena
Massie, Charlie
Anand, Shubha
Haddow, Tiffany
Dodd, Marc
Deng, Wenhan
Martin, Ezequiel
Howden, Philip
Wenlock, Stephanie
Sala, Evis
Symeonides, Stefan
Ho, Lynn
Baxter, Jennifer
Leslie, Stuart
McLaren, Duncan
Brush, John
O’Donnell, Marie
Griffin, Alisa
Orr, Ruth
Cowan, Catriona
Powles, Thomas
Pejnovic, Anna
Tincey, Sophia
Grant, Lee
Nuttall, Martin
Willsher, Lucy
Barnett, Christian
Nicol, David
Larkin, James
Fielding, Alison
Smith, Christopher G.
Bex, Axel
Boleti, Ekaterini
Carruthers, Jade
Eisen, Tim
Fife, Kate
Godoy, Angela
Hamid, Abdel
Laird, Alexander
Leung, Steve
Malik, Jahangeer
Mumtaz, Faiz
Oades, Grenville
Priest, Andrew N.
Riddick, Antony C. P.
Venugopal, Balaji
Welsh, Michelle
Riddle, Kathleen
Jones, Robert J.
- License Information
-
More Information
Article History
Received: 21 October 2024
Accepted: 18 March 2025
First Online: 28 April 2025
Competing interests
: The authors declare the following competing interests: H.P.: AstraZeneca (studentship). F.A.G.: research support from GE Healthcare; Grants from GSK; Consulting for AZ on behalf of the University of Cambridge. M.C.O.: 52 North Health Ltd (co-founder and employee), GE HealthCare (research funding), GSK (speaking fees). G.D.S.: Financial Interests – Evinova (consultancy, workshop on new product), British Journal of Urology International (Associate Editor) - paid role, NATCAN (Clinical Director (surgery) for the National Kidney Cancer), Audit (paid role), National Institute for Health and Care Excellence (Topic Advisor of kidney cancer guideline - paid role), AstraZeneca (Institutional Funding of the WIRE clinical trial); Non-Financial Interests - Getting It Right First Time (Principal Investigator, Chair of the kidney cancer pathway), British Association of Urological Surgeons (Member), European Association of Urology (Member); Other – MSD (Funded attendance at ESMO 2023). J.J.: Financial interests: Evinova (consultancy, workshop on new product), AstraZeneca (Institutional Funding of the WIRE clinical trial). The remaining authors declare no competing interests.
